ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT ID: NCT07147296
Last Updated: 2026-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2025-10-17
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant.
Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (active or sham) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
NCT05941819
The Up-LIFT Study of Non-Invasive ARC Therapy for Spinal Cord Injury
NCT04697472
Therapeutic Mechanisms of Epidural Spinal Cord Stimulation
NCT05556902
Spinal Cord Stimulation for Chronic and Intractable Back Pain
NCT00370695
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
NCT06000592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active Group
ARC-IM System with active stimulation since day 0
ARC-IM System Implantation
Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
ARC-IM Therapy (active)
The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
Sham Group
ARC-IM System without active stimulation before the open-label phase of the study (3 month post-implant)
ARC-IM System Implantation
Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
ARC-IM Therapy (sham)
The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation (after 3 months of sham stimulation) at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARC-IM System Implantation
Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator
ARC-IM Therapy (active)
The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
ARC-IM Therapy (sham)
The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation (after 3 months of sham stimulation) at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.
3. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.
4. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score
5. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.
6. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.
7. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.
8. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation
9. Stable medical, physical, and psychological condition as considered by the investigators.
10. Stable dose of blood pressure medication for 30-days prior to enrollment into the study . Stability will be defined as no changes to medication regimens based on treating physician instructions.
11. Subjects who are on long-term antihypertensive treatment must discontinue these medications no less than 30 days prior to enrollment in the study. This requirement does not apply to antihypertensive agents administered for the acute management of autonomic dysreflexia (AD)
12. If the subject requires daily continuous support from a personal caregiver, the presence of a caregiver during the study visits is mandatory.
13. Willing and able to provide informed consent.
14. Stated willingness to comply with all study procedures and availability for the duration of the study.
15. Willing and able to comply with the instructions for use, operate the study devices, and comply with this clinical investigation plan
Exclusion Criteria
2. Subject has diseases and conditions that would increase the morbidity and mortality of the surgical procedures required by the study.
3. Subject has a history of physiologic hypotension prior to SCI
4. Subject has a history of unexpected blood pressure instability related to medications
5. Inability to withhold antiplatelet/anticoagulation agents perioperatively.
6. History of myocardial infarction or cerebrovascular event within the past 6 months. or
7. History of chronic/recurrent severe cardiac arrythmias (e.g., ventricular tachycardia, ventricular fibrillation, third degree atrioventricular block)
8. Evidence of clinically significant underlying cardiac conditions on Holter monitoring performed at screening including but not limited to arrhythmias (e.g., atrial fibrillation, ventricular tachycardia),
9. Evidence of ischemic changes or prolonged QT interval (QTc \> of 450 ms for males and 470 ms for females) identified on EKG during screening,
10. Subjects with a known diagnosis of heart failure, including but not limited to New York Heart Association (NYHA) Class I-IV, or with evidence of clinically significant left ventricular dysfunction (ejection fraction \< 40%) as determined by echocardiogram during screening or within the past 6 months,
11. Current renal/kidney, hepatic, or other concomitant disorders deemed severe by the Investigator including those ones that could be linked to severe autonomic dysreflexia.
12. Requires continuous ventilator support.
13. Imaging (MRI, CT, X-ray) findings within the last 12 months that contraindicate lead placement
14. Known allergic reaction to implanted materials
15. Requires continuous/frequent/any transcutaneous spinal cord stimulation treatment.
16. Has any active implanted medical device (e.g. baclofen pump, pacemaker).
17. Inability to receive a pre-operative MRI.
18. Female subject who is pregnant, breastfeeding or planning to become pregnant or breastfeed. Women of child-bearing potential must have a negative pregnancy test completed at baseline visit per site standard test.
19. Presence of pressure sore at time of screening or baseline graded stage 3 or 4 .
20. Subject is enrolled or intends to participate in another clinical drug and/or device study or registry that may interfere with the results of this study, as determined by ONWARD Medical personnel.
21. Presence of other anatomic or comorbid conditions, or other medical, social, or psychologic conditions such as severe uncontrolled neuropathic pain, depression, history of alcohol or substance abuse, history of schizophrenia or psychotic illness, severe personality disorder or other significant psychiatric or cognitive disorders that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ONWARD Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Craig Hospital
Englewood, Colorado, United States
UofL Health - Frazier Rehabilitation Institute
Louisville, Kentucky, United States
Spaulding Rehabilitation
Cambridge, Massachusetts, United States
Oregon Health & Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONWD-IM-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.